PharmaCyte Biotech Inc (PMCB) - Total Liabilities
Based on the latest financial reports, PharmaCyte Biotech Inc (PMCB) has total liabilities worth $11.77 Million USD as of April 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PharmaCyte Biotech Inc (PMCB) long-term investment share to see how much of total assets are deployed in long-term investments.
PharmaCyte Biotech Inc - Total Liabilities Trend (2002–2026)
This chart illustrates how PharmaCyte Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PMCB current and non-current assets.
PharmaCyte Biotech Inc Competitors by Total Liabilities
The table below lists competitors of PharmaCyte Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Krakatoa Resources Ltd
AU:KTA
|
Australia | AU$356.39K |
|
Project Planning Service Public Company Limited
BK:PPS
|
Thailand | ฿302.93 Million |
|
Ho Hup Construction Company
KLSE:5169
|
Malaysia | RM298.27 Million |
|
SEKUR PRIVATE DATA LTD.
F:GDT0
|
Germany | €385.21K |
|
Magic Empire Global Limited
NASDAQ:MEGL
|
USA | $4.61 Million |
|
GB Group plc
LSE:GBG
|
UK | GBX193.77 Million |
|
Azucar Minerals Ltd
V:AMZ
|
Canada | CA$127.25K |
Liability Composition Analysis (2002–2026)
This chart breaks down PharmaCyte Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See PharmaCyte Biotech Inc net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 45.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PharmaCyte Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PharmaCyte Biotech Inc (2002–2026)
The table below shows the annual total liabilities of PharmaCyte Biotech Inc from 2002 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-04-30 | $11.77 Million | +259.21% |
| 2025-04-30 | $3.28 Million | -83.93% |
| 2024-04-30 | $20.39 Million | +3375.95% |
| 2023-04-30 | $586.58K | -16.72% |
| 2022-04-30 | $704.37K | -2.82% |
| 2021-04-30 | $724.78K | -32.75% |
| 2020-04-30 | $1.08 Million | +45.07% |
| 2019-04-30 | $742.85K | +15.32% |
| 2018-04-30 | $644.17K | +11.02% |
| 2017-04-30 | $580.25K | -9.00% |
| 2016-04-30 | $637.64K | -68.31% |
| 2015-04-30 | $2.01 Million | +438.56% |
| 2014-04-30 | $373.67K | -90.16% |
| 2013-04-30 | $3.80 Million | +0.29% |
| 2012-04-30 | $3.79 Million | -4.59% |
| 2011-04-30 | $3.97 Million | +25.88% |
| 2010-04-30 | $3.15 Million | +8.14% |
| 2009-04-30 | $2.92 Million | +1515.02% |
| 2008-04-30 | $180.56K | +51.98% |
| 2007-04-30 | $118.81K | -83.59% |
| 2006-04-30 | $723.89K | -55.63% |
| 2005-04-30 | $1.63 Million | +395.68% |
| 2004-04-30 | $329.13K | +12934.97% |
| 2003-04-30 | $2.52K | -67.85% |
| 2002-04-30 | $7.86K | -- |
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including adv… Read more